Industry wants broader health technology assessments for drugs, says global report
This article was originally published in SRA
Health technology assessments for medicines should be broader, says an international report commissioned by R&D-based pharmaceutical industry associations from Europe, the US and Australia1,2.
You may also be interested in...
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.
In an exclusive interview, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.
Criticism of Novartis/Avexis’s controversial lottery style managed access program for Zolgensma has come largely from Europe, while other countries in Latin America and Asia have been far more receptive.